Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs

Vistagen announced a collaboration with GATC Health to apply GATC's Operon AI platform and Derisq predictive reports across Vistagen's lead clinical-stage programs. The work covers potential next Phase 3 fasedienol study in social anxiety disorder (LSAS endpoint) plus potential Phase 2 studies of itruvone (MDD) and refisolone (menopausal hot flashes).

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.